SCHOTT Pharma AG & Co. KGaA (1SXP) - Total Assets
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) holds total assets worth €1.44 Billion EUR (≈ $1.69 Billion USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SCHOTT Pharma AG & Co. KGaA cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
SCHOTT Pharma AG & Co. KGaA - Total Assets Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's total assets have evolved over time, based on quarterly financial data. See SCHOTT Pharma AG & Co. KGaA book value and equity for net asset value and shareholders' equity analysis.
SCHOTT Pharma AG & Co. KGaA - Asset Composition Analysis
Current Asset Composition (June 2024)
SCHOTT Pharma AG & Co. KGaA's total assets of €1.44 Billion consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.6% |
| Accounts Receivable | €174.89 Million | 12.1% |
| Inventory | €140.44 Million | 9.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.12 Million | 0.1% |
| Goodwill | €29.35 Million | 2.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SCHOTT Pharma AG & Co. KGaA market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCHOTT Pharma AG & Co. KGaA's current assets represent 40.8% of total assets in 2024, an increase from 40.1% in 2020.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 3.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
SCHOTT Pharma AG & Co. KGaA Competitors by Total Assets
Key competitors of SCHOTT Pharma AG & Co. KGaA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
|
China | CN¥4.11 Billion |
|
Daxor Corporation
NASDAQ:DXR
|
USA | $35.90 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
SCHOTT Pharma AG & Co. KGaA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.33 | 1.72 |
| Quick Ratio | 1.03 | 0.94 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €153.12 Million | €117.19 Million | €231.50 Million |
SCHOTT Pharma AG & Co. KGaA - Advanced Valuation Insights
This section examines the relationship between SCHOTT Pharma AG & Co. KGaA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | €1.44 Billion |
| Market Capitalization | $2.39 Billion USD |
Valuation Analysis
Above Book Valuation: The market values SCHOTT Pharma AG & Co. KGaA's assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: SCHOTT Pharma AG & Co. KGaA's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual total assets of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €1.44 Billion ≈ $1.69 Billion |
+17.08% |
| 2023-06-30 | €1.23 Billion ≈ $1.44 Billion |
+2.95% |
| 2022-06-30 | €1.20 Billion ≈ $1.40 Billion |
+61.71% |
| 2021-06-30 | €739.89 Million ≈ $865.02 Million |
+24.14% |
| 2020-06-30 | €596.02 Million ≈ $696.81 Million |
-- |
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more